European Cancer Organisation
login

Oncopolicy Forum 2012: Speaker presentations and interactive debates

VIDEOS OF EACH SESSIONS

OPENING SESSION

  • Welcome address by Cornelis J.H. van de Velde, ECCO President
  • Welcome address: Julio E Celis, Chair of ECCO Policy Committee
  • Opening Speech by Video address by Máire Geoghegan-Quinn European Commissioner for Research,
    Innovation and Science
  • Speaker: Maria-Jose Vidal-Ragout, Head of Unit, Medical Research, DG Research and Innovation, European Commission
  • Opening Lecture: Personalised Cancer Medicine – Defining the concept and state-of-the-art by Alexander M.M. Eggermont, President, European Academy of Cancer Sciences and Director, Institut Gustave Roussy

SESSION 1: KEY ISSUES IN PERSONALISED CANCER MEDICINE

  • Towards Common Standards (Omics technology, bioinformatics, system biology, imaging, infrastructures)
    Speaker: Peter Lichter, Head of Department, Molecular  Genetics,  Cancer Research Centre (DKFZ), Heidelberg, Germany
  • Towards a faster uptake in clinical practice by Martine Piccart, ECCO President-elect
  • Regulatory issues by Jonas Bergh, Karolinska Institute, Sweden
  • Discussion

SESSION 2: KEY ISSUES IN PERSONALISED CANCER MEDICINE

  • Health economics issues by Bengt Jönsson, Professor in Health Economics, Stockholm School of
    Economics, Sweden
  • Training of Healthcare Professionals by Angelo Paradiso,  Giovanni Paolo II National Cancer Institute,  Bari, Italy
  • Educating patients as partners in personalised medicine by Jan Geissler, ECCO Patient Advisory Committee

SESSION 3: ONCOPOLICY 2020 - PERSONALISED CANCER MEDICINE: THE WAY FORWARD

  • EPAAC WP8: Towards coordination of cancer research in Europe Public and private partnerships to stimulate drug development through academic clinical research. From a national to a European dimension
    Speaker: F. Calvo, Deputy General Director, INCa
  • The German Consortium for Translational Cancer Research by Otmar D. Wiestler, Director, German Cancer research Centre (DKFZ), Heidelberg, Germany
  • Rare Cancers Europe – a case study by Paolo Casali, Istituto Nazionale Tumori, Milan, Italy
  • European Alliance for Personalised Medicine (EAPM) by Bernard Malavaud, EAPM
  • Accelerating Europe's Health Research and Innovation Through Strategic, Scientific-Led Actions: The European Council for Health Research
    Speaker: Julio E. Celis, Vice-President, Alliance for Biomedical Research in Europe
  • Discussion

CONCLUSIONS: Concluding remarks by Cornelis J.H. van de Velde, ECCO President

 

 

 

OPENING SESSION

Welcome address by Cornelis J.H. van de Velde, ECCO President

 

 

Welcome address by Julio E Celis, Chair of ECCO Policy Committee

 

 

Opening Speech by Video address by Máire Geoghegan-Quinn European Commissioner for Research, Innovation and Science (Copyright: European Commission)

 

 

Speaker: Maria-Jose Vidal-Ragout, Head of Unit, Medical Research, DG Research and Innovation, European Commission

 

 

Opening Lecture: Personalised Cancer Medicine – Defining the concept and state-of-the-art by Alexander M.M. Eggermont, President, European Academy of Cancer Sciences and Director, Institut Gustave Roussy

 

 

SESSION 1 – KEY ISSUES IN PERSONALISED CANCER MEDICINE

 

Towards Common Standards (Omics technology, bioinformatics, system biology, imaging, infrastructures), by Peter Lichter, Head of Department, Molecular  Genetics,  Cancer Research Centre (DKFZ), Heidelberg, Germany

 

  

Towards a faster uptake in clinical practice by Martine Piccart, ECCO President-elect

 

 

Regulatory issues by Jonas Bergh, Karolinska Institute, Sweden

 

 

Discussion

 

 

SESSION 2 – KEY ISSUES IN PERSONALISED CANCER MEDICINE

 
Health economics issues by Bengt Jönsson, Professor in Health Economics, Stockholm School of
Economics, Sweden

 

 

Training of Healthcare Professionals by Angelo Paradiso, Giovanni Paolo II National Cancer Institute,  Bari, Italy

 

 

Educating patients as partners in personalised medicine by Jan Geissler, ECCO Patient Advisory Committee

 

 

 

SESSION 3 – ONCOPOLICY 2020 - PERSONALISED CANCER MEDICINE: THE WAY FORWARD
 

EPAAC WP8: Towards coordination of cancer research in Europe Public and private partnerships to stimulate drug development through academic clinical research. From a national to a European dimension by F. Calvo, Deputy General Director, INCa

 

 

The German Consortium for Translational Cancer Research by Otmar D. Wiestler, Director, German Cancer research Centre (DKFZ), Heidelberg, Germany

 

 

Rare Cancers Europe – a case study by Paolo Casali, Istituto Nazionale Tumori, Milan, Italy

 

 

European Alliance for Personalised Medicine (EAPM) by Bernard Malavaud, EAPM

 

 

Accelerating Europe's Health Research and Innovation Through Strategic, Scientific-Led Actions: The European Council for Health Research, by Julio E. Celis, Chair of ECCO Policy Committee; Vice-President, Alliance for Biomedical Research in Europe

 

  

Discussion

 

 

CONCLUSIONS
  

Concluding remarks by Cornelis J.H. van de Velde, ECCO President

 

 

PRINT THIS PAGE Page last modified: